PMID- 37793337
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240206
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 30
IP  - 1
DP  - 2024 Jan
TI  - Prognostic Impact of Serum Homocysteine-Lowering Therapy on Patients with 
      Hemorrhagic Stroke and Its Influence on National Institutes of Health Stroke 
      Scale and China Stroke Scale Scores.
PG  - 381-385
LID - AT9243 [pii]
AB  - OBJECTIVE: This study aimed to investigate the prognostic impact of serum 
      homocysteine-lowering therapy on patients with hemorrhagic stroke (HS) and its 
      influence on their National Institutes of Health Stroke Scale (NIHSS) and China 
      Stroke Scale (CSS) scores. METHODS: A double-blind study involving 120 patients 
      with HS and hyperhomocysteinemia (Hhcy) who were admitted to our hospital was 
      conducted in 2021. They were evenly divided into two groups: the control group 
      (n=60) received low-dose folic acid, methylcobalamin, and vitamin B6 as part of 
      serum homocysteine-lowering therapy, while the study group (n=60) received 
      high-dose folic acid, methylcobalamin, and vitamin B6. The prognosis of each 
      group was compared using the NIHSS and CSS to assess the neurological function of 
      the patients. RESULTS: Before treatment, the levels of oxidative stress markers 
      and vascular endothelial function markers were comparable between the two groups 
      (t = 0.051, 0.015, 0.010, 0.011, 0.013, 0.022, P = .960, .988, .992, 0.991, .989, 
      0.982). However, after treatment, the study group exhibited higher levels of MDA 
      and ET-1 compared to the control group (t = 3.418, 1.978, P < .001). 
      Additionally, SOD, GSH-Px, and PON1 levels were lower in the study group (t = 
      3.435, 3.783, 2.735, 3.893, P < .001). The NIHSS scores before treatment were 
      comparable among patients (t = 0.058, P = 0.954), but after treatment, the study 
      group showed significantly lower NIHSS scores (t = 20.105, P < .001). Similarly, 
      the CSS scores before treatment were comparable (t = 0.046, P = .963), but the 
      CSS scores in the study group after treatment were significantly lower (t = 
      5.027, P < .001). CONCLUSIONS: High-dose folic acid, methylcobalamin, and vitamin 
      B6 as part of serum homocysteine-lowering therapy can improve oxidative stress 
      and vascular endothelial function in HS patients. This treatment also enhances 
      prognosis and ameliorates neurological deficits. Therefore, it holds significant 
      clinical potential and should be considered for broader adoption.
FAU - An, Xiangyang
AU  - An X
FAU - Du, Xinrui
AU  - Du X
FAU - Yang, Bo
AU  - Yang B
FAU - Zhai, Naichi
AU  - Zhai N
FAU - Cui, Laixian
AU  - Cui L
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 935E97BOY8 (Folic Acid)
RN  - 8059-24-3 (Vitamin B 6)
RN  - EC 3.1.8.1 (PON1 protein, human)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
SB  - IM
MH  - United States
MH  - Humans
MH  - Prognosis
MH  - *Hemorrhagic Stroke/drug therapy
MH  - Folic Acid/therapeutic use
MH  - *Stroke/drug therapy
MH  - Vitamin B 6/therapeutic use
MH  - National Institutes of Health (U.S.)
MH  - Aryldialkylphosphatase
EDAT- 2023/10/05 01:00
MHDA- 2024/02/05 06:42
CRDT- 2023/10/04 18:12
PHST- 2024/02/05 06:42 [medline]
PHST- 2023/10/05 01:00 [pubmed]
PHST- 2023/10/04 18:12 [entrez]
AID - AT9243 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2024 Jan;30(1):381-385.